DalCor Pharmaceuticals (Canada)
Corporate brand
UnclaimedA biopharmaceutical company focused on developing dalcetrapib, a pharmacogenetic precision medicine for cardiovascular disease.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
DalCor Pharmaceuticals is a biopharmaceutical company focused on addressing cardiovascular disease. Its purpose is to deliver dalcetrapib, the first pharmacogenetic precision medicine in cardiovascular disease that specifically targets patients with the AA genotype at rs1967309 location in the ADCY9 gene. Dalcetrapib is currently being evaluated in the Dal-GenE-2 (DAL-302) Phase 3 clinical trial. The company holds the worldwide exclusive license to develop, manufacture and commercialise dalcetrapib.
History
DalCor Pharmaceuticals is a biopharmaceutical company focused on addressing cardiovascular disease. Its purpose is to deliver dalcetrapib, the first pharmacogenetic precision medicine in cardiovascular disease that specifically targets patients with the AA genotype at rs1967309 location in the ADCY9 gene. Dalcetrapib is currently being evaluated in the Dal-GenE-2 (DAL-302) Phase 3 cardiovascular clinical outcomes confirmatory trial. The company holds the worldwide exclusive license to develop, manufacture and commercialise dalcetrapib.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/dalcor-pharmaceuticals-canada · Editorial policy · How profiles are compiled